Caribou Biosciences, Inc. (CRBU) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Caribou Biosciences is a clinical-stage biopharmaceutical company developing allogeneic CAR-T cell therapies using its proprietary chRDNA genome-editing platform. The company is currently advancing two primary candidates: vispa-cel (anti-CD19) for B-cell non-Hodgkin lymphoma and CB-011 (anti-BCMA) for multiple myeloma. The company has no approved products and relies on licensing revenue and capital raises to fund operations.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $2.4 million | $2.4 million |
| Net Loss | $(25.1) million | $(40.0) million |
| Loss Per Share (Basic/Diluted) | $(0.26) | $(0.43) |
| Operating Expenses | $28.7 million | $45.3 million |
| Cash Used in Operating Activities | $(27.0) million | $(36.7) million |
| Cash, Cash Equivalents, and Marketable Securities | $118.6 million | $142.8 million (Dec 31, 2025) |
| Accumulated Deficit | $(621.6) million | $(488.4) million (Mar 31, 2025) |
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by $16.6 million (37%) year-over-year. Research and Development (R&D) expenses dropped $14.9 million, primarily due to reduced external CRO/CMO activities ($7.7 million) and workforce reductions ($2.8 million in personnel costs).
- Improved Loss Profile: Net loss narrowed by $14.9 million to $25.1 million, driven by the significant reduction in operating costs.
- Revenue Stability: Licensing revenue remained flat at approximately $2.4 million, derived from collaboration agreements and milestone payments.
- Capital Activity: The company raised $2.2 million net proceeds through its At-The-Market (ATM) equity offering program during the quarter, selling approximately 1.08 million shares.
Outlook, Management Commentary, and Risks
- Clinical Progress:
- vispa-cel: Management announced an optimized profile cohort (N=35) with an 86% overall response rate (ORR) and 63% complete response (CR) rate. The company has aligned with the FDA on the design for a pivotal Phase 3 trial (ANTLER-3) in relapsed/refractory large B-cell lymphoma.
- CB-011: Dose escalation is complete. The recommended dose for expansion (RDE) is 450x10^6 cells. In a BCMA-naive cohort, the therapy showed a 92% ORR and 75% CR rate.
- Liquidity: Management expects existing cash and marketable securities ($118.6 million) to fund operations for at least the next 12 months. However, the company anticipates substantial future expenses to advance Phase 3 trials and may need to raise additional capital.
- Risks: Key risks include the uncertainty of clinical trial outcomes, the need for continued capital raises, potential dilution from equity offerings, and the complexity of manufacturing allogeneic cell therapies. The company has an accumulated deficit of $621.6 million and has not achieved profitability.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $118.6 million cash balance against the projected costs of the upcoming Phase 3 vispa-cel trial.
- ATM Program Capacity: Confirm remaining capacity under the ATM program ($93.4 million available as of March 31, 2026) and potential dilution impact.
- Revenue Concentration: Review Note 2 for revenue concentration; three parties accounted for 72.2% of revenue in Q1 2026.
- Stock-Based Compensation: Monitor the $13.4 million of unrecognized stock-based compensation expense related to options and $6.1 million related to RSUs, which will impact future operating expenses.
- Clinical Milestones: Track the initiation and enrollment rates of the ANTLER-3 Phase 3 trial and the CaMMouflage Phase 1 expansion cohorts.